|
|
||||
|
NAME Stefano Campaner |
POSITION TITLE Team Leader
|
|||
|
EDUCATION/TRAINING |
||||
|
INSTITUTION AND LOCATION |
DEGREE |
YEAR(s) |
FIELD OF STUDY |
|
|
|
|
|
|
|
|
University of Milan, Italy |
Degree |
1992 |
Biology |
|
|
Department of General Physiology and Biochemistry, University of Milan, Italy |
PhD |
1993-1997 |
Biochemistry |
|
|
Genetics Branch, National Cancer Institute, NIH (USA) |
Post-doc |
1998-2003 |
Cell cycle-Tumor biology |
|
|
European Institute of Oncology, Milan, Italy |
Post-doc |
2003-2010 |
Cell cycle-Tumor biology |
|
|
European Institute of Oncology, Milan, Italy |
Staff-Scientist |
2010-2011 |
Cell cycle-Tumor biology |
|
|
IIT@SEMM, Center for Genomic Science, Fondazione Istituto Italiano di Tecnologia (IIT) |
Team Leader |
2012 |
Cell cycle-Tumor biology |
|
Positions and Employment
1993-1997: PhD student in Biochemistry, at the Department of General Physiology and Biochemistry,University of Milan, Italy .
1998-2003: Post-doctoral fellow, National Cancer Institute, National Institute of Health, USA
2003-2009: Post-doctoral fellow , European Institute of Oncology, Milan, Italy
2009-2012: Professor of Molecular and Cellular Oncology, University of Milano-Bicocca, Italy
2009-2011: Staff Scientist, European Institute of Oncology, Milan, Italy
2012: Team leader, Cancer Biology, Center for Genomic Science of IIT@SEMM, Milan Italy
Honors
Recipient of the 2002 Fellow Award for Research Excellence at NIH
Fogarty post-doctoral fellowship award, from January 1998 to June 2003
Keystone Symposia scholarship funded by the International Society of Differentiation (July-2008)
Patents
PHARMACEUTICAL COMPOSITION AND METHOD FOR REGULATING ABNORMAL CELLULAR PROLIFERATION PCT Patent Application No. PCT IL2006-001324.
1. Campaner S, Amati B. Two sides of the Myc-induced DNA damage response. from
tumor suppression to tumor maintenance. Cell Div. 2012 Feb 28;7(1).6.
2. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF,
D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B,
Fernandez-Capetillo O. Exploiting oncogene-induced replicative stress for the
selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011 Nov
27;18(12).1331-5.
3. Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, Testa G. The
methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage
response in vivo. Mol Cell. 2011 Aug 19;43(4).681-8.
4. Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de
Marco A, Biffo S. Impairment of cytoplasmic eIF6 activity restricts
lymphomagenesis and tumor progression without affecting normal growth. Cancer
Cell. 2011 Jun 14;19(6).765-75.
5. Campaner S, Doni M, Verrecchia A, Faga’ G, Bianchi L, Amati B. Myc, Cdk2 and
cellular senescence. Old players, new game. Cell Cycle. 2010 Sep
15;9(18).3655-61.
6. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker
T, Perna D, Tronnersjö S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG,
Amati B. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat
Cell Biol. 2010 Jan;12(1).54-9; sup pp 1-14.
7. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi
G, Fontanella E, Menard S, Tagliabue E. Tumor-initiating cells of HER2-positive
carcinoma cell lines express the highest oncoprotein levels and are sensitive to
trastuzumab. Clin Cancer Res. 2009 Mar 15;15(6).2010-21.
8. Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Menard S, Tagliabue
E. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2
protein overexpression without gene amplification. Cancer Res. 2007 Jun
1;67(11).5308-17.
9. Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E, Goldstein I,
Stettner N, Harmelin A, Eldar-Finkelman H, Campaner S, Kirsch I, Izraeli S. The
SIL gene is essential for mitotic entry and survival of cancer cells. Cancer Res.
2007 May 1;67(9).4022-7. Epub 2007 Apr 24. Erratum in. Cancer Res. 2007 Jun
15;67(12).5998.
10. Campaner S, Kaldis P, Izraeli S, Kirsch IR. Sil phosphorylation in a Pin1
binding domain affects the duration of the spindle checkpoint. Mol Cell Biol.
2005 Aug;25(15).6660-72.
11. Erez A, Perelman M, Hewitt SM, Cojacaru G, Goldberg I, Shahar I, Yaron P,
Muler I, Campaner S, Amariglio N, Rechavi G, Kirsch IR, Krupsky M, Kaminski N,
Izraeli S. Sil overexpression in lung cancer characterizes tumors with increased
mitotic activity. Oncogene. 2004 Jul 8;23(31).5371-7.
12. Izraeli S, Lowe LA, Bertness VL, Campaner S, Hahn H, Kirsch IR, Kuehn MR.
Genetic evidence that Sil is required for the Sonic Hedgehog response pathway.
Genesis. 2001 Oct;31(2).72-7.
13. Molla G, Porrini D, Job V, Motteran L, Vegezzi C, Campaner S, Pilone MS,
Pollegioni L. Role of arginine 285 in the active site of Rhodotorula gracilis
D-amino acid oxidase. A site-directed mutagenesis study. J Biol Chem. 2000 Aug
11;275(32).24715-21.
14. Campaner S, Pollegioni L, Ross BD, Pilone MS. Limited proteolysis and
site-directed mutagenesis reveal the origin of microheterogeneity in Rhodotorula
gracilis D-amino acid oxidase. Biochem J. 1998 Mar 1;330 ( Pt 2).615-21.
15. Pollegioni L, Molla G, Campaner S, Martegani E, Pilone MS. Cloning,
sequencing and expression in E. coli of a D-amino acid oxidase cDNA from
Rhodotorula gracilis active on cephalosporin C. J Biotechnol. 1997 Oct
17;58(2).115-23.
16. Pollegioni L, Campaner S, Raibekas AA, Pilone MS. Identification of a
reactive cysteine in the flavin-binding domain of Rhodotorula gracilis D-amino
acid oxidase. Arch Biochem Biophys. 1997 Jul 1;343(1).1-5..
17. Pollegioni L, Campaner S, Raibekas AA, Pilone MS. Reactivity of sulfhydryl
groups of Rhodotorula gracilis D-amino acid oxidase. Biochem Soc Trans. 1996
Feb;24(1).21S.
L’Istituto Italiano di Tecnologia (IIT) è una fondazione di diritto privato - cfr. determinazione Corte dei Conti 23/2015 “IIT è una fondazione da inquadrare fra gli organismi di diritto pubblico con la scelta di un modello di organizzazione di diritto privato per rispondere all’esigenza di assicurare procedure più snelle nella selezione non solo nell’ambito nazionale dei collaboratori, scienziati e ricercatori ”.
IIT è sotto la vigilanza del Ministero dell'Istruzione, dell'Università e della Ricerca e del Ministero dell'Economia e delle Finanze ed è stato istituito con la Legge 326/2003. La Fondazione ha l'obiettivo di promuovere l'eccellenza nella ricerca di base e in quella applicata e di favorire lo sviluppo del sistema economico nazionale. La costruzione dei laboratori iniziata nel 2006 si è conclusa nel 2009.
Lo staff complessivo di IIT conta circa 1440 persone. L’area scientifica è rappresentata da circa l’85% del personale. Il 45% dei ricercatori proviene dall’estero: di questi, il 29% è costituito da stranieri provenienti da oltre 50 Paesi e il 16% da italiani rientrati. Oggi il personale scientifico è composto da circa 60 principal investigators, circa 110 ricercatori e tecnologi di staff, circa 350 post doc, circa 500 studenti di dottorato e borsisti, circa 130 tecnici. Oltre 330 posti su 1400 creati su fondi esterni. Età media 34 anni. 41% donne / 59 % uomini.
Nel 2015 IIT ha ricevuto finanziamenti pubblici per circa 96 milioni di euro (80% del budget), conseguendo fondi esterni per 22 milioni di euro (20% budget) provenienti da 18 progetti europei, 17 finanziamenti da istituzioni nazionali e internazionali, circa 60 progetti industriali
La produzione di IIT ad oggi vanta circa 6990 pubblicazioni, oltre 130 finanziamenti Europei e 11 ERC, più di 350 domande di brevetto attive, oltre 12 start up costituite e altrettante in fase di lancio. Dal 2009 l’attività scientifica è stata ulteriormente rafforzata con la creazione di dieci centri di ricerca nel territorio nazionale (a Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) e internazionale (MIT ed Harvard negli USA) che, unitamente al Laboratorio Centrale di Genova, sviluppano i programmi di ricerca del piano scientifico 2015-2017.
Istituto Italiano di Tecnologia (IIT) is a public research institute that adopts the organizational model of a private law foundation. IIT is overseen by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero dell'Economia e delle Finanze (the Italian Ministries of Education, Economy and Finance). The Institute was set up according to Italian law 326/2003 with the objective of promoting excellence in basic and applied research andfostering Italy’s economic development. Construction of the Laboratories started in 2006 and finished in 2009.
IIT has an overall staff of about 1,440 people. The scientific staff covers about 85% of the total. Out of 45% of researchers coming from abroad 29% are foreigners coming from more than 50 countries and 16% are returned Italians. The scientific staff currently consists of approximately 60 Principal Investigators, 110 researchers and technologists, 350 post-docs and 500 PhD students and grant holders and 130 technicians. External funding has allowed the creation of more than 330 positions . The average age is 34 and the gender balance proportion is 41% female against 59% male.
In 2015 IIT received 96 million euros in public funding (accounting for 80% of its budget) and obtained 22 million euros in external funding (accounting for 20% of its budget). External funding comes from 18 European Projects, other 17 national and international competitive projects and approximately 60 industrial projects.
So far IIT accounts for: about 6990 publications, more than 130 European grants and 11 ERC grants, more than 350 patents or patent applications, 12 up start-ups and as many which are about to be launched. The Institute’s scientific activity has been further strengthened since 2009 with the establishment of 11 research nodes throughout Italy (Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) and abroad (MIT and Harvard University, USA), which, along with the Genoa-based Central Lab, implement the research programs included in the 2015-2017 Strategic Plan.
